Is TB-500 Legal in Maryland? How to Access It Legally

What Is TB-500 and Why Does Its Legal Status Matter?

TB-500 is a shorthand label for a synthetic peptide derived from thymosin beta-4, specifically the tetrapeptide fragment Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline). Thymosin beta-4 itself is a naturally occurring 43-amino-acid protein present in most human and animal tissues, with well-documented roles in actin sequestration, wound repair, and inflammatory modulation.

Understanding the legal framework matters for two reasons. First, anyone purchasing or prescribing TB-500 outside a valid regulatory pathway faces real legal exposure. Second, patients who need tissue-repair support deserve accurate information rather than vendor marketing.

The Difference Between Thymosin Beta-4 and TB-500

The full thymosin beta-4 protein and the shorter TB-500 synthetic fragment are often conflated in online discussions. They are not the same compound. Most clinical research has examined the full protein; the commercial peptide sold as "TB-500" is the truncated fragment. This distinction matters because FDA regulatory decisions may apply differently to each form, and prescribers must be precise in any compounding prescription.

Why Maryland Has No Separate TB-500 Law

Maryland does not maintain a state-level controlled-substances schedule for peptides like TB-500. The state pharmacy board defers to the federal Controlled Substances Act and FDA regulations for non-scheduled drugs. That means the entire legal question reduces to federal law, interpreted and enforced by the FDA and the Drug Enforcement Administration, applied by Maryland-licensed practitioners and pharmacists.

Federal Framework: FDA Regulation of Bulk Drug Substances

The FDA regulates pharmaceutical compounding under the Federal Food, Drug, and Cosmetic Act (FD&C Act), primarily through two pathways established or clarified by the Drug Quality and Security Act of 2013: Section 503A (traditional compounding pharmacies) and Section 503B (outsourcing facilities). Both pathways rely on specific lists of bulk drug substances that may or may not be used.

The 503A Bulks List and TB-500

Under Section 503A, traditional compounding pharmacies may prepare individualized compounds for specific patients without full FDA approval, provided they use bulk drug substances that appear on an FDA-approved list, are components of FDA-approved drugs, or appear in the United States Pharmacopeia (USP) or National Formulary. FDA 503A guidance clarifies this structure.

TB-500 (thymosin beta-4 and its synthetic fragments) has been placed by the FDA in the Category 2 "do not use" category following its evaluation process. This classification signals that the agency found insufficient evidence of clinical usefulness or raised safety concerns. A Category 2 placement means a 503A pharmacy cannot lawfully compound TB-500 for human use. The FDA's complete bulks list for 503A can be reviewed at the agency's compounding page.

The 503B Outsourcing Facility Pathway

Section 503B outsourcing facilities can produce larger batches of compounded drugs without patient-specific prescriptions, but only from substances on a separate FDA-approved bulk drug substances list for outsourcing facilities. TB-500 does not appear on that positive list either. The FDA outsourcing facility bulk drug list is published here.

This dual absence, from both the 503A and 503B permitted lists, is the core of TB-500's current legal problem in every U.S. State, Maryland included.

FDA Enforcement Discretion: A Narrow and Temporary Opening

The FDA has periodically exercised enforcement discretion for certain peptides during transitional regulatory periods, allowing some compounders to continue operations while the formal listing process concluded. These enforcement discretion periods are time-limited, product-specific, and do not create a right to compound. Practitioners relying on enforcement discretion arguments should confirm the current status directly with the FDA's Center for Drug Evaluation and Research (CDER) or with a health-law attorney, because these windows open and close without broad public announcement.

Maryland-Specific Regulatory Layer

While Maryland adds no new prohibition on TB-500 beyond federal law, the state's regulatory infrastructure shapes how federal rules are applied in practice.

Maryland Board of Pharmacy

The Maryland Board of Pharmacy licenses and disciplines pharmacists and pharmacies operating in the state. Compounding pharmacies in Maryland must comply with United States Pharmacopeia Chapters 795 (non-sterile) and 797 (sterile) standards, in addition to federal law. A Maryland-licensed pharmacy that compounds TB-500 for human use in violation of the 503A bulks list would be subject to Board discipline, not just FDA action. The Board's enforcement authority is documented in the Maryland Pharmacy Act, Md. Code Ann., Health Occ. §§ 12-101 et seq.

Maryland Medical Practice Act and Prescriber Liability

Maryland physicians and other licensed prescribers operate under the Maryland Medical Practice Act, Md. Code Ann., Health Occ. §§ 14-101 et seq. Writing a prescription for a compound that cannot lawfully be prepared by a 503A pharmacy exposes a prescriber to potential Board of Physicians discipline on grounds of unprofessional conduct or prescribing outside accepted standards of care.

That does not mean prescribers can never discuss TB-500 with patients. It means they cannot generate a valid compounding prescription for a substance the receiving pharmacy is prohibited from using.

What Maryland Law Says About "Research Chemical" Purchases

Vendors often market TB-500 as a "research chemical" with disclaimers like "not for human use." Under federal law, 21 U.S.C. § 331 prohibits the introduction of misbranded or unapproved new drugs into interstate commerce. When a consumer purchases a "research chemical" peptide with the intent to self-administer, that product meets the legal definition of an unapproved new drug used in humans. Maryland's consumer protection statutes do not create an exception. The "research use only" label is a vendor shield, not a legal authorization for the buyer.

Clinical Evidence: What Does the Research Actually Show?

TB-500 and its parent molecule thymosin beta-4 have generated genuine scientific interest. Reviewing that evidence honestly is part of giving patients accurate information.

Preclinical and Animal Data

Thymosin beta-4 has demonstrated wound-healing effects in multiple animal models. A 2010 study published in the Annals of the New York Academy of Sciences examined thymosin beta-4's role in cardiac repair after myocardial infarction in rodent models, finding improved cardiomyocyte survival and reduced fibrosis. Bock-Marquette I et al., 2010 (PubMed) describes part of this preclinical work. Animal data on tendon and muscle repair have similarly shown pro-repair signaling through actin-binding and anti-inflammatory pathways.

Human Clinical Trial Field

Human data are sparse. A Phase II trial by RegeneRx Biopharmaceuticals examined topical thymosin beta-4 for pressure ulcer healing and found modest but statistically significant improvement in wound closure rates versus vehicle control. RGN-352 clinical program data referenced at ClinicalTrials.gov provide some context, though these studies used the full protein topically, not the injectable synthetic fragment sold as TB-500.

No large randomized controlled trial has evaluated injectable synthetic TB-500 (Ac-SDKP fragment) in humans for musculoskeletal injury. The absence of Phase III data is one reason the FDA placed thymosin beta-4 preparations on the Category 2 list. As the FDA's own guidance on bulk drug substance evaluation states, the agency considers "the physical and chemical characterization of the substance," "known or potential safety risks," and "the available evidence of effectiveness."

The Gap Between Athlete Use and Clinical Validation

TB-500 has become popular in athletic recovery communities, partly because it is not currently listed as a prohibited substance in the same way as certain anabolic agents, though the World Anti-Doping Agency (WADA) prohibits peptide hormones and related substances under its Prohibited List. Popularity in online forums is not a substitute for controlled trial data, and Maryland patients should understand that testimonial evidence carries no clinical weight.

The Only Lawful Path to TB-500 in Maryland Right Now

Given the regulatory field described above, there is currently no routine lawful path for a Maryland patient to obtain injectable TB-500 from a domestic compounding pharmacy. The steps below describe what a hypothetical compliant access path would require if and when regulatory status changes, and what patients can do today.

Step 1: Consult a Licensed Maryland Prescriber

A board-certified physician, DO, or other licensed prescriber in Maryland is the starting point for any peptide therapy discussion. That prescriber must review your medical history, establish a diagnosis or therapeutic rationale, and determine whether any lawful treatment option exists. Telehealth consultations with Maryland-licensed providers count, provided the provider holds an active Maryland license and complies with the Maryland Telehealth statutes.

Step 2: Confirm Current FDA Enforcement Status

Your prescriber or their practice's legal counsel should confirm, at the time of any prescribing decision, whether the FDA has issued any updated enforcement discretion guidance for thymosin beta-4 preparations. The FDA's CDER division updates compounding guidance periodically. What was impermissible in 2024 may have a new status in 2025 or 2026, and vice versa.

Step 3: Use Only a State-Licensed, USP-Compliant Compounding Pharmacy

If enforcement discretion or a future positive listing makes 503A compounding permissible again, the pharmacy must hold a valid Maryland Board of Pharmacy license (or be a licensed out-of-state pharmacy shipping into Maryland under an appropriate reciprocal license), meet USP 797 sterility standards for injectable compounds, and be able to document the source and certificate of analysis for all bulk drug substances used. No prescription from a Maryland-licensed physician can legally be filled by an unlicensed vendor operating outside these frameworks.

Step 4: Avoid "Research Chemical" Vendors Entirely

Purchasing TB-500 from a website that labels it "for research use only" and shipping it to a Maryland address for self-injection is not a legal gray area. It is the purchase of an unapproved new drug for human use, a violation of federal law that also exposes the buyer to unknown product quality, sterility failures, and inaccurate dosing. Independent third-party testing of peptides sold through these channels has repeatedly found concentration discrepancies of 20 to 50 percent and contamination with bacterial endotoxins. A 2022 JAMA Internal Medicine analysis of compounded and gray-market peptides documented widespread purity and potency problems across similar product categories.

Alternatives With Established Legal and Clinical Pathways in Maryland

Patients seeking tissue repair, recovery support, or anti-inflammatory therapy have several options with clearer regulatory standing.

BPC-157

BPC-157 (body protection compound-157) has a similar preclinical profile and is also on the FDA's 503A Category 2 list as of early 2024 enforcement updates. The regulatory situation for BPC-157 parallels TB-500 closely. Patients should ask their prescriber for the current status before assuming availability.

FDA-Approved Wound-Healing and Anti-Inflammatory Agents

Platelet-rich plasma (PRP) therapy, prepared from the patient's own blood and administered by a licensed Maryland provider, is a legally straightforward option for musculoskeletal repair indications. PRP is classified as a same-surgical-procedure exception under FDA tissue regulations. Other anti-inflammatory options, including licensed corticosteroid injections, nonsteroidal anti-inflammatory drugs, and physical therapy protocols, have documented efficacy and no regulatory ambiguity.

Peptides With Clearer 503A Status

Some peptides, including sermorelin (a growth-hormone releasing hormone analogue), appear on the FDA's 503A bulk drug substances list and can be compounded by Maryland-licensed pharmacies for appropriate patients under a valid prescription. The FDA's 503A bulks list is the authoritative reference; providers and patients should check it directly rather than relying on vendor claims.

What Maryland Patients Should Ask Their Provider

A productive clinical conversation about TB-500 in Maryland should cover at least these points.

First, ask your provider what the current FDA enforcement discretion status is for thymosin beta-4 preparations. The answer changes, and a provider who does not know the current status should find out before writing any prescription.

Second, ask which licensed compounding pharmacy the provider works with, and request documentation that the pharmacy holds a valid Maryland Board of Pharmacy license and a current USP 797 certification.

Third, ask what clinical evidence supports the proposed use of TB-500 for your specific condition. Given the absence of Phase III human data on the injectable synthetic fragment, any evidence-based answer will be honest about the limitations.

Fourth, ask about documented alternatives. If a provider cannot name any lawful alternative, that is a signal to seek a second opinion from a prescriber familiar with the compounding regulatory framework.

As the FDA's own compounding guidance documents state: "Compounded drugs are not FDA-approved. This means FDA has not verified their safety, effectiveness, or quality before they are marketed." This statement applies directly to any TB-500 preparation, regardless of how it is marketed or by whom it is prescribed. FDA drug compounding overview.

Summary of the Legal Status Matrix

The table below condenses the access framework for Maryland residents considering TB-500.

| Access Route | Legal in Maryland? | Notes | |---|---|---| | 503A compounding pharmacy (patient-specific Rx) | No (Category 2 placement) | Barred unless FDA changes listing | | 503B outsourcing facility | No | Not on 503B permitted list | | FDA enforcement discretion window | Conditional / time-limited | Verify current status with CDER | | Research chemical vendor (self-purchase) | No | Unapproved new drug; federal violation | | FDA-approved finished drug | No approved product exists | No NDA or BLA on file for TB-500 | | Clinical trial enrollment | Possible | Check ClinicalTrials.gov for open studies |

Maryland patients who want legitimate access to peptide therapies should work with a telehealth or in-person provider who stays current on FDA compounding list updates, because the regulatory picture for specific peptides can shift within a single calendar year. Check the FDA's current 503A bulks list directly before any prescribing or dispensing decision, and verify any compounding pharmacy's license through the Maryland Board of Pharmacy license verification tool.